Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2023

Open Access 08-10-2023 | Hyperparathyroidism | Case Report

Brown tumor due to primary hyperparathyroidism in a familial case: a case report

Authors: Zongping Diao, Jianquan Zhang, Jiaqi Zhao, Weihu Sun, Zhengguo Pu

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Background

Primary hyperparathyroidism (PHPT) is an uncommon disorder characterised by hypercalcemia with an increased parathyroid hormone level. We reported a PHPT familial case with two subjects, a father and a daughter, and both of them had suffered from the brown tumor.

Case presentation

The proband, a 43-year-old patient, developed parathyroid adenomas at the age of 15; a histologically confirmed right parathyroid adenoma was removed by parathyroidectomy; and after six months follow-up, the serum calcium level was normalised. At the age of thirty-three, a CT scan of his head and neck revealed a mass in the right maxilla, as well as PHPT (i.e., left inferior parathyroid adenoma). Then, he underwent a biopsy of an exophytic lesion in the right maxilla and was diagnosed by pathology as a brown tumor, with the serum calcium and PTH levels at 2.78 mmol/L and 221 pg/mL, respectively. Subsequently, the patient took a left inferior parathyroid microwave ablation with ultrasound guidance. After three months of follow-up, the serum calcium and PTH levels returned to normal, and the brown tumor was resolved. After three years, it mineralised as revealed in a CT scan. By the time he was 43 years old, during the 28-year follow-up period, the serum calcium and PTH levels were still within the normal range, and there was no discomfort reported. He has consistently taken calcium supplements throughout the 28 years. Since the initial diagnosis, his blood indicators of kidney function have been normal, and ultrasound showed renal calculus in the right kidney and a normal left kidney. The proband’s daughter, a 15-year-old girl, experienced left upper extremity pain for ten months. CT scan revealed a mass in the distal left radius, and a giant cell tumor was suspected. A surgical internal fixation was performed, and the pathology showed a brown tumor. Laboratory tests revealed a serum parathyroid hormone (PTH) level of 1554pg/mL, calcium level of 3.14 mmol/L, phosphorus level of 0.72 mmol/L, and alkaline phosphatase level of 1892 U/L. Given the osteitic changes and elevated levels of calcium and PTH, ultrasonography was performed, after which a mass was detected measuring 19 × 9 × 7 mm mixed with solid components and cystic fluid in the right thyroid gland. The results of 99mTc-MIBI scintigraphy confirmed the abnormal accumulation of 99mTc-MIBI in the right thyroid gland but not seen in the bilateral parathyroid glands. The patient underwent thyroidectomy, and the postoperative pathology report indicated an intra-thyroid ectopic parathyroid adenoma. The serum calcium and PTH levels became normal at 4 h after surgery. One to three months after operation, the serum calcium level was low, while the serum PTH level was high. Then, the patient was advised to take calcium supplements. Until the sixth month after the operation, the serum calcium level and serum PTH level returned to normal, and the bone pain was relieved. The patient’s blood tests for kidney function remained normal. There was no evidence of bilateral kidney disease (such as nephrolithiasis or nephrocalcinosis) detected by ultrasound scan. There were several similarities in the state of illness between these two subjects. Both the father and the daughter developed parathyroid adenomas at the age of 15, and there was no lesion in other endocrine glands. And genetic testing revealed mutations in the CDC73 genes in both father and daughter. On the other hand, there were also a few differences. The father’s first signs of brown tumor were in the right maxilla, while the daughter’s appeared in the distal left radius. The father presented pathological changes in the left and right parathyroid glands, whereas the daughter presented with an ectopic parathyroid adenoma in the right thyroid gland.

Conclusion

We report a familial case in which father and daughter were diagnosed to have brown tumors due to parathyroid adenoma and ectopic parathyroid adenoma, and genetic testing revealed CDC73 gene mutations in both. Therefore, in the diagnostic and differential process of young patients having bone disease, clinicians should not only focus on the clinical manifestations of the skeleton, but also implement a comprehensive analysis of systemic symptoms, considering the possibility that the patient has familial PHPT.
Literature
1.
go back to reference Levine DS, Wiseman SM. Fusion imaging for parathyroid localization in primary hyperparathyroidism. Expert Rev Anticancer Ther. 2010;10(3):353–63.CrossRefPubMed Levine DS, Wiseman SM. Fusion imaging for parathyroid localization in primary hyperparathyroidism. Expert Rev Anticancer Ther. 2010;10(3):353–63.CrossRefPubMed
2.
go back to reference Park HS, Lee YH, Hong N, Won D, Rhee Y. Germline mutations related to primary hyperparathyroidism identified by Next-Generation sequencing. Front Endocrinol (Lausanne). 2022;13:853171.CrossRefPubMedPubMedCentral Park HS, Lee YH, Hong N, Won D, Rhee Y. Germline mutations related to primary hyperparathyroidism identified by Next-Generation sequencing. Front Endocrinol (Lausanne). 2022;13:853171.CrossRefPubMedPubMedCentral
3.
go back to reference Alagaratnam S, Kurzawinski TR. Aetiology, diagnosis and surgical treatment of primary hyperparathyroidism in children: new trends. Horm Res Paediatr. 2015;83(6):365–75.CrossRef Alagaratnam S, Kurzawinski TR. Aetiology, diagnosis and surgical treatment of primary hyperparathyroidism in children: new trends. Horm Res Paediatr. 2015;83(6):365–75.CrossRef
4.
go back to reference Van der Tuin K, Tops CM, Adank MA, Cobben JM, Hamdy NA, Jongmans MC, et al. CDC73-related disorders: clinical manifestations and case detection in primary hyperparathyroidism. J Clin Endocrinol Metab. 2017;102(12):4534–40.CrossRefPubMed Van der Tuin K, Tops CM, Adank MA, Cobben JM, Hamdy NA, Jongmans MC, et al. CDC73-related disorders: clinical manifestations and case detection in primary hyperparathyroidism. J Clin Endocrinol Metab. 2017;102(12):4534–40.CrossRefPubMed
5.
go back to reference Zhu CY, Sturgeon C, Yeh MW. Diagnosis and management of primary hyperparathyroidism. JAMA. 2020;24(12):1186–7.CrossRef Zhu CY, Sturgeon C, Yeh MW. Diagnosis and management of primary hyperparathyroidism. JAMA. 2020;24(12):1186–7.CrossRef
6.
go back to reference Duan K, Gomez Hernandez K, Mete O. Clinicopathological correlates of hyperparathyroidism. J Clin Pathol. 2015;68(10):771–87.CrossRefPubMed Duan K, Gomez Hernandez K, Mete O. Clinicopathological correlates of hyperparathyroidism. J Clin Pathol. 2015;68(10):771–87.CrossRefPubMed
8.
go back to reference Iacobone M, Carnaille B, Palazzo FF, Vriens M. Hereditary hyperparathyroidism–a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2015;400(8):867–86.CrossRefPubMed Iacobone M, Carnaille B, Palazzo FF, Vriens M. Hereditary hyperparathyroidism–a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2015;400(8):867–86.CrossRefPubMed
9.
go back to reference Diacinti D, Cipriani C, Biamonte F, et al. Imaging technologies in the differential diagnosis and follow-up of brown tumor in primary hyperparathyroidism: case report and review of the literature. Bone Rep. 2020;14:100745.CrossRefPubMedPubMedCentral Diacinti D, Cipriani C, Biamonte F, et al. Imaging technologies in the differential diagnosis and follow-up of brown tumor in primary hyperparathyroidism: case report and review of the literature. Bone Rep. 2020;14:100745.CrossRefPubMedPubMedCentral
10.
go back to reference Minisola S, Arnold A, Belaya Z, et al. Epidemiology, pathophysiology, and Genetics of primary hyperparathyroidism. J Bone Miner Res. 2022;37(11):2315–29.CrossRefPubMed Minisola S, Arnold A, Belaya Z, et al. Epidemiology, pathophysiology, and Genetics of primary hyperparathyroidism. J Bone Miner Res. 2022;37(11):2315–29.CrossRefPubMed
11.
go back to reference Newey PJ, Bowl MR, Cranston T, Thakker RV. Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat. 2010;31(3):295–307.CrossRefPubMed Newey PJ, Bowl MR, Cranston T, Thakker RV. Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat. 2010;31(3):295–307.CrossRefPubMed
12.
go back to reference Iijima Y, Ishikawa M, Iwai S, et al. Robotic resection of ectopic mediastinal parathyroid adenoma with intraoperative parathyroid hormone monitoring: a case report. J Cardiothorac Surg. 2022;17(1):195.CrossRefPubMedPubMedCentral Iijima Y, Ishikawa M, Iwai S, et al. Robotic resection of ectopic mediastinal parathyroid adenoma with intraoperative parathyroid hormone monitoring: a case report. J Cardiothorac Surg. 2022;17(1):195.CrossRefPubMedPubMedCentral
13.
go back to reference Wang X, Wang M, Zhang J, et al. Humeral brown tumor as first presentation of primary hyperparathyroidism caused by ectopic parathyroid adenomas: report of two cases and review of literature. Int J Clin Exp Pathol. 2014;7(10):7094–9.PubMedPubMedCentral Wang X, Wang M, Zhang J, et al. Humeral brown tumor as first presentation of primary hyperparathyroidism caused by ectopic parathyroid adenomas: report of two cases and review of literature. Int J Clin Exp Pathol. 2014;7(10):7094–9.PubMedPubMedCentral
14.
go back to reference Dhiwakar M, Damodharan S, Rajeshwari KM, Mehta S. Ectopic parathyroid adenoma presenting as facial expansile growths. B-ENT. 2016;12(1):73–6.PubMed Dhiwakar M, Damodharan S, Rajeshwari KM, Mehta S. Ectopic parathyroid adenoma presenting as facial expansile growths. B-ENT. 2016;12(1):73–6.PubMed
15.
go back to reference Haber RS, Kim CK, Inabnet WB. Ultrasonography for preoperative localization of enlarged parathyroid glands in primary hyperparathyroidism: comparison with (99m)technetium sestamibi scintigraphy. Clin Endocrinol (Oxf). 2002;57(2):241–9.CrossRefPubMed Haber RS, Kim CK, Inabnet WB. Ultrasonography for preoperative localization of enlarged parathyroid glands in primary hyperparathyroidism: comparison with (99m)technetium sestamibi scintigraphy. Clin Endocrinol (Oxf). 2002;57(2):241–9.CrossRefPubMed
16.
go back to reference Taterra D, Wong LM, Vikse J, et al. The prevalence and anatomy of parathyroid glands: a meta-analysis with implications for parathyroid surgery. Langenbecks Arch Surg. 2019;404(1):63–70.CrossRefPubMedPubMedCentral Taterra D, Wong LM, Vikse J, et al. The prevalence and anatomy of parathyroid glands: a meta-analysis with implications for parathyroid surgery. Langenbecks Arch Surg. 2019;404(1):63–70.CrossRefPubMedPubMedCentral
17.
go back to reference Callender GG, Grubbs EG, Vu T, et al. The fallen one: the inferior parathyroid gland that descends into the mediastinum. J Am Coll Surg. 2009;208(5):887–93. discussion 893-5.CrossRefPubMed Callender GG, Grubbs EG, Vu T, et al. The fallen one: the inferior parathyroid gland that descends into the mediastinum. J Am Coll Surg. 2009;208(5):887–93. discussion 893-5.CrossRefPubMed
18.
go back to reference Wakamatsu H, Noguchi S, Yamashita H, et al. Technetium-99m tetrofosmin for parathyroid scintigraphy: a direct comparison with (99m)Tc-MIBI, (201)tl, MRI and US. Eur J Nucl Med. 2001;28(12):1817–27.CrossRefPubMed Wakamatsu H, Noguchi S, Yamashita H, et al. Technetium-99m tetrofosmin for parathyroid scintigraphy: a direct comparison with (99m)Tc-MIBI, (201)tl, MRI and US. Eur J Nucl Med. 2001;28(12):1817–27.CrossRefPubMed
19.
go back to reference Machado NN, Wilhelm SM. Diagnosis and evaluation of primary hyperparathyroidism. Surg Clin North Am. 2019;99(4):649–66.CrossRefPubMed Machado NN, Wilhelm SM. Diagnosis and evaluation of primary hyperparathyroidism. Surg Clin North Am. 2019;99(4):649–66.CrossRefPubMed
20.
go back to reference Loh KC, Duh QY, Shoback D, Gee L, Siperstein A, Clark OH. Clinical profile of primary hyperparathyroidism in adolescents and young adults. Clin Endocrinol (Oxf). 1998;48(4):435–43.CrossRefPubMed Loh KC, Duh QY, Shoback D, Gee L, Siperstein A, Clark OH. Clinical profile of primary hyperparathyroidism in adolescents and young adults. Clin Endocrinol (Oxf). 1998;48(4):435–43.CrossRefPubMed
21.
go back to reference Macfarlane DP, Yu N, Leese GP. Subclinical and asymptomatic parathyroid disease: implications of emerging data. Lancet Diabetes Endocrinol. 2013;1(4):329–40.CrossRefPubMed Macfarlane DP, Yu N, Leese GP. Subclinical and asymptomatic parathyroid disease: implications of emerging data. Lancet Diabetes Endocrinol. 2013;1(4):329–40.CrossRefPubMed
22.
go back to reference Nilsson IL, Norenstedt S, Zedenius J, Pernow Y, Bränström R. Primary hyperparathyroidism, hypercalciuria, and bone recovery after parathyroidectomy. Surgery. 2017;162(2):429–36.CrossRefPubMed Nilsson IL, Norenstedt S, Zedenius J, Pernow Y, Bränström R. Primary hyperparathyroidism, hypercalciuria, and bone recovery after parathyroidectomy. Surgery. 2017;162(2):429–36.CrossRefPubMed
23.
go back to reference Mehrabibahar M, Mousavi Z, Sadeghi R, Layegh P, Nouri M, Asadi M. Feasibility and safety of minimally invasive radioguided parathyroidectomy using very low intraoperative dose of Tc-99m MIBI. Int J Surg. 2017;39:229–33.CrossRefPubMed Mehrabibahar M, Mousavi Z, Sadeghi R, Layegh P, Nouri M, Asadi M. Feasibility and safety of minimally invasive radioguided parathyroidectomy using very low intraoperative dose of Tc-99m MIBI. Int J Surg. 2017;39:229–33.CrossRefPubMed
24.
go back to reference Reséndiz-Colosia JA, Rodríguez-Cuevas SA, Flores-Díaz R, et al. Evolution of maxillofacial brown tumors after parathyroidectomy in primary hyperparathyroidism. Head Neck. 2008;30(11):1497–504.CrossRefPubMed Reséndiz-Colosia JA, Rodríguez-Cuevas SA, Flores-Díaz R, et al. Evolution of maxillofacial brown tumors after parathyroidectomy in primary hyperparathyroidism. Head Neck. 2008;30(11):1497–504.CrossRefPubMed
25.
go back to reference Casteràs A, Darder L, Zafon C et al. Brown tumor of the jaw after pregnancy and lactation in a MEN patient. Endocrinol Diabetes Metab Case Rep. 2016;2016:16–0111. Casteràs A, Darder L, Zafon C et al. Brown tumor of the jaw after pregnancy and lactation in a MEN patient. Endocrinol Diabetes Metab Case Rep. 2016;2016:16–0111.
26.
go back to reference Szabo Yamashita T, Gudmundsdottir H, Foster TR, et al. Pediatric primary hyperparathyroidism: Surgical pathology and long-term outcomes in sporadic and familial cases. Am J Surg. 2023;225(4):699–702.CrossRefPubMed Szabo Yamashita T, Gudmundsdottir H, Foster TR, et al. Pediatric primary hyperparathyroidism: Surgical pathology and long-term outcomes in sporadic and familial cases. Am J Surg. 2023;225(4):699–702.CrossRefPubMed
Metadata
Title
Brown tumor due to primary hyperparathyroidism in a familial case: a case report
Authors
Zongping Diao
Jianquan Zhang
Jiaqi Zhao
Weihu Sun
Zhengguo Pu
Publication date
08-10-2023
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01475-3

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine